Pharmaceutical Executive, Jan 1, 2014 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Jan 1, 2014
Features
Russia's Bet on Biopharma
By William Looney
Can innovation trump ideology? Russia faces a stark choice in betting on the visible hand of government in promoting a "world class" biopharmaceutical sector, writes William Looney.
Pharm Exec's Annual Industry Outlook 2014
By Ben Comer , Julian Upton
For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive — muddling through is so yesterday.
The 7 Habits of Highly Effective Competitors
By Stan Bernard, MD
Lessons to win in a shifting market dynamic
Column
Biosimilars or Bust
By Ben Comer
Where are the biosimilars to help cut costs as the first wave of biologics, or complex, small molecule respiratory drugs, for example, go off patent? They've arrived in Europe, but the U.S. lags...
Pharma Challenges for 2014
By Jill Wechsler
Pricing and personalized medicine are key themes shaping drug development and marketing
Innovation: The Moneyball Test
Successful innovation now has to align with key metrics of value—can an old baseball metaphor help guide the way?
From the Editor
For Russia—Tough Love
By William Looney
Pharm Exec begins its 34th year with a feature on Russia's ambitious plans to build a homegrown biopharma business. Back in 1980, the biotech industry did not exst. Drugs were still classified as chemicals, developed from the random screening of many thoughts.

ADVERTISEMENT

Click here